Battlefield wound infection prevention and treatment (BWI P&T): barrier combination product development

The Defense Health Agency (DHA) is conducting market research through this Request for Information (RFI) to identify commercial solutions for a barrier combination product designed to prevent and treat battlefield wound infections. This product will serve as a component within a broader Family of Systems approach aimed at developing medical materiel solutions for use in austere environments where medical resources are limited and evacuation may be prolonged. The barrier combination product must meet four minimum essential characteristics: it must provide a safe physical barrier with antimicrobial properties effective against bacterial and fungal infections, maintain efficacy during storage at ambient and extreme temperatures, sustain product stability for at least 12 months, and achieve a minimum Technology Readiness Level (TRL) of 4. Respondents must submit detailed company and product information demonstrating their capability to perform the scope of work, with submissions formatted in Arial 12-point font and submitted electronically to Jeanette Collins. The deadline for all RFI responses is 2:00 PM Eastern on January 20, 2026, providing approximately 48 days for interested parties to prepare and submit their responses.

This pre-solicitation notice includes no set-aside designations and does not identify any potential incumbents or current contractors. No specific award value or budget range is provided in the RFI materials, as this is a market research phase intended to inform future procurement decisions and refine requirements rather than commit to a specific contract amount. The RFI requires respondents to include comprehensive company information such as business classification, tax identification, CAGE code, UEI number, and socio-economic classifications, along with details regarding Federal Supply Schedule contracts or acceptable cost accounting systems. Respondents must also provide detailed product information and demonstrate how their solutions align with the minimum essential characteristics outlined in Attachment 3. The barrier combination product is intended for use across multiple roles of care, spanning from point of injury in austere battlefield environments to hospital care settings, with applications for both Department of Defense and commercial markets.